
PAKISTAN’s healthcare debates often overlook a paradox that deserves closer attention. The practice of alternative medicine systems, like herbal, unani, homeopathy and many others, remains an important source of affordable and accessible care, particularly in rural and underserved communities. For many families, these systems offer a cheaper first point of contact when conventional healthcare is either distant or unaffordable.
In that limited sense, alternative medicine systems may help reduce household expenditure and ease pressure on the already overburdened public facilities. However, affordability should not be confused with safety, and access should not come at the cost of delayed diagnosis.
The real concern is not about such systems of practice, and not even with the practitioners who work within a properly regulated framework. The main concern is what happens when regulation is weak, products are poorly controlled, practitioners are unregistered, or alternative treatment is allowed to substitute for timely evidence-based care in serious illnesses.
A patient with tuberculosis, cancer, diabetes or hypertension may initially find alternative medicines to be inexpensive, but far greater personal and public costs await such a patient when diagnosis and effective treatment are delayed.
Another, less visible concern is the safety of certain concentrated preparations. Some formulations may contain mineral or metallic ingredients, while mother tinctures contain appreciable quantities of their source substances.
Poor manufacturing, inappropriate dose and prolonged use can, therefore, carry the risk of toxicity. Liver and kidney injury, adverse reactions and complications can ultimately result in hospitalisation and, in severe cases, prolonged treatment, dialysis or transplantation. Yet, Pakistan lacks sufficiently robust national data to quantify how frequently such harm occurs or how much of the country’s disease and economic burden can be attributed to these practices. This evidence gap itself is a policy problem.
The answer, therefore, should be neither blanket rejection nor uncritical promotion. Pakistan needs stronger professional regulation, quality assurance, pharma covigilance and clear referral mechanisms for serious or potentially life-threatening conditions. All manufacturers should be required to generate meaningful post-market safety data, while adverse reactions should be systematically reported and investigated.
Most importantly, the country needs independent research comparing the costs and outcomes of regulated traditional medicine with conventional care. Only then can policymakers determine where these systems genuinely reduce the economic burden, and where they may, inadvertently, add to it. In healthcare, the cheapest treatment is not necessarily the least costly one. Sometimes the price of delay is paid much later and paid by the patient, the family and the healthcare system alike.
Ilahi Bux
Hyderabad
Published in Dawn, November 16th, 2026


























